ERBB2 and breast carcinoma: In conclusion, this meta-analysis suggests that compared with conventional sb-taxanes, neoadjuvant nab-paclitaxel could improve pCR rate and EFS in non-metastatic breast cancer and could be especially beneficial in the HER2-negative HR-positive and high-risk disease types.